Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07294872
PHASE1

A Study of TIL in Advanced Solid Tumors (CZ)

Sponsor: Shanghai Juncell Therapeutics

View on ClinicalTrials.gov

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Official title: A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-05-08

Completion Date

2029-09-20

Last Updated

2026-01-16

Healthy Volunteers

No

Interventions

BIOLOGICAL

GC101TIL

A tumor sample is resected from each participant and cultured ex vivo to expand the population of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL.

Locations (1)

Sichuan Cancer Hospital & Institute, Sichuan Cancer Center

Chengdu, China